• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 438907 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414771733 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414771733 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Antares Pharma Ranks the Highest in Terms of Revenue Per Employee in the Health Care Supplies Industry (AIS, VIVO, CERS)

Published on Fri, 02/08/2013 - 11:18
By Peter Chu

Below are the three companies in the Health Care Supplies industry with the highest Revenue Per Employee (RPE). Analysts use RPE as a measure to compare the productivity of companies in the same industry.

Antares Pharma (AMEX:AIS) is highest with an RPE of $1.1 million. Antares Pharma, Inc. develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. The Company distributes its needle-free injector systems in various countries. Antares also conducts research and development with transdermal gel products and has several products in clinical evaluation with partners.

Potential upside of 61.6% exists for Antares Pharma, based on a current level of $3.30 and analysts' average consensus price target of $5.33. The stock should find initial support at its 50-day moving average (MA) of $3.04 and further support at its 200-day MA of $2.60.

Meridian Bioscience (NASDAQ:VIVO) is next with an RPE of $629,000.

Finishing up the top three is Cerus (NASDAQ:CERS), with an RPE of $464,000.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Stock Investors Bid Up Shares of Thorate...

Thoratec (NASDAQ:THOR) is one of today's biggest movers, up 2.5% to $27.06. The S&P is ...

Methanex Bullish Moving Average Crossove...

Methanex (NASDAQ:MEOH) crossed over its 10-day moving average of $57.42 on a volume of ...

Highest Projected Earnings Growth in the...

Below are the three companies in the Food Distributors industry with the highest projec ...

Stock Investors Bid Up Shares of Nidec, ...

Nidec (NYSE:NJ) is one of today's notable stocks on the rise, up 2.5% to $16.50. The S ...

Trinity Industries Crosses Above its 10-...

Trinity Industries (NYSE:TRN) crossed over its 10-day moving average of $34.83 on a vol ...

Tetra Tech has the Highest Projected Ear...

Below are the three companies in the Environmental & Facilities Services industry with ...

Stock Investors Bid Up Shares of Viasat,...

Viasat (NASDAQ:VSAT) is a company whose shares are active, trading 2.5% higher to $61.8 ...

Williams-Sonoma Crosses Above its 10-day...

Williams-Sonoma (NYSE:WSM) shares have crossed bullishly above their 10-day moving aver ...